证券代码：301111 证券简称：粤万年青 公告编号：2025-047 广东万年青制药股份有限公司 董事会 2025 年 9 月 15 日 1 本次活动将采用网络远程的方式举行，投资者可登录"全景路演"网站 （http://rs.p5w.net），或关注微信公众号：全景财经，或下载全景路演 APP， 参与本次互动交流，活动时间为 2025 年 9 月 19 日（周五）15:30-17:00。 届时,公司董事长、总裁欧先涛先生，董事、副总裁、财务总监兼董事会秘 书陈秀燕女士及独立董事李华青先生将在线就公司经营情况等投资者关心的问 题，与投资者进行沟通与交流，欢迎广大投资者踊跃参与！ 特此公告。 广东万年青制药股份有限公司 关于参加广东辖区上市公司2025年半年报业绩说明会暨投资 者网上集体接待日活动的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 为进一步加强与投资者的互动交流，广东万年青制药股份有限公司（以下简 称"公司"）将参加由广东证监局、广东上市公司协会与深圳市全景网络有限公 司联合举办的"广东辖区上市公司 2025 年半年报业绩说明会暨投资者网上 ...

Group 1 - The company announced the convening of a workers' representative meeting on September 11, 2025 [2] - During the meeting, Lin Kejun was elected as the employee representative director of the company's third board of directors [2]

关于广东万年青制药股份有限公司 2025 年第三次临时股东大会的法律意见 广东万年青制药股份有限公司： 根据中国证券监督管理委员会发布的《上市公司股东会规则》(以下简称《股 东会规则》)的要求，国浩律师(广州)事务所(以下简称"本所")接受广东万年 青制药股份有限公司(以下简称"万年青")的委托，指派李彩霞、郭佳律师(以 下简称"本所律师")出席万年青 2025 年第三次临时股东大会(以下简称"本次 股东大会")，对本次股东大会的召集与召开程序、出席会议人员与召集人的资 格、表决程序与表决结果等重要事项出具法律意见。 北 京 上 海 深 圳 杭 州 广 州 昆 明 天 津 成 都 宁 波 福 州 西 安 南 京 南 宁 济 南 重 庆 苏 州 长 沙 太 原 武 汉 贵 阳 乌 鲁 木 齐 郑 州 石 家 庄 合 肥 海 南 青 岛 南 昌 大 连 银 川 拉 孜 香 港 巴 黎 马 德 里 斯 德 哥 尔 摩 纽 约 • 马 来 西 亚 广州市天河区华夏路 32 号太平洋金融大厦 19 楼 邮编：510623 电话：(+86)(20) 3879 9345 传真：(+86)(20) 3879 9345-200 ...

广东万年青制药股份有限公司 关于选举产生第三届董事会职工代表董事的公告 证券代码：301111 证券简称：粤万年青 公告编号：2025-046 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 为完善公司治理结构，保障广东万年青制药股份有限公司（以下简称"公司"） 董事会的正常运作，根据《中华人民共和国公司法》《公司章程》等相关规定， 公司于 2025 年 9 月 11 日召开了职工代表大会。经与会职工代表讨论表决，会议 选举林可筠女士（简历详见附件）为公司第三届董事会职工代表董事。 林可筠女士将与公司现任第三届董事会非职工代表董事共同组成公司第三 届董事会，任期自本次职工代表大会审议通过之日起至第三届董事会届满之日止。 上述职工代表董事符合《中华人民共和国公司法》等法律法规规定的任职条 件。董事会中兼任公司高级管理人员职务的董事以及由职工代表担任的董事，人 数总计不超过公司董事总数的二分之一。 特此公告。 广东万年青制药股份有限公司 董事会 2025 年 9 月 11 日 1 附件：第三届董事会职工代表董事简历 林可筠简历 林可筠，女，1990 年 10 月生 ...

广东万年青制药股份有限公司 2025年第三次临时股东大会决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 证券代码：301111 证券简称：粤万年青 公告编号：2025-045 1、本次股东大会不存在否决议案的情形。 2、本次股东大会不涉及变更以往股东大会已通过的决议。 一、会议召开情况 1、召开时间 （1）现场会议召开时间：2025 年 9 月 11 日下午 15:00 （2）网络投票时间：深圳证券交易所（"深交所"）交易系统投票时间为： 2025 年 9 月 11 日 9:15-9:25，9:30-11:30，13:00-15:00；深交所互联网投票系 统投票时间为：2025 年 9 月 11 日 9:15-15:00。 2、现场会议召开地点：广东省汕头市长平路 94 号万年青国际医疗港会议室 3、会议召集人：董事会 4、会议召开方式：本次股东大会采用现场表决与网络投票相结合的方式。 5、会议主持人：董事长欧先涛先生 6. 本次会议的召集、召开符合《中华人民共和国公司法》《上市公司股东 会规则》《深圳证券交易所创业板股票上市规则》等有关 ...

Group 1 - The stock price of Yue Wannianqing closed at 16.53 yuan on August 27, 2025, down 6.03% from the previous trading day, with a trading volume of 68,224 hands and a transaction amount of 116 million yuan [1] - Yue Wannianqing's main business includes the production and sales of pharmaceuticals, as well as healthcare services, health management, and health consumer products, aiming to build a "Traditional Chinese Medicine +" development pattern to create a comprehensive health industry ecosystem covering "prevention-diagnosis-rehabilitation" [1] - According to the company's 2025 semi-annual report, the revenue for the first half of the year was 155 million yuan, a year-on-year increase of 1.6%, but the net profit attributable to shareholders was a loss of 7.22 million yuan, a year-on-year increase in loss of 147.8% [1] Group 2 - The company reported a loss of 3.78 million yuan in the second quarter, a year-on-year increase in loss of 212.4%, attributing the profit decline to increased costs from new business expansions during the market cultivation period [1] - On August 27, the net outflow of main funds was 440,500 yuan, with a cumulative net outflow of 2.72 million yuan over the past five days [1]

Group 1 - The company reported a total operating revenue of 155 million yuan, an increase of 2.41 million yuan compared to the same period last year, marking three consecutive years of growth, with a year-on-year increase of 1.58% [1] - The net profit attributable to shareholders was -7.22 million yuan, and the net cash inflow from operating activities was -6.03 million yuan, an increase of 11.82 million yuan compared to the same period last year [1] Group 2 - The company's latest debt-to-asset ratio is 18.85%, ranking 7th among disclosed peers [3] - The latest gross profit margin is 63.21%, ranking 15th among disclosed peers, with an increase of 1.05 percentage points from the previous quarter and an increase of 3.65 percentage points from the same period last year [3] - The latest return on equity (ROE) is -0.96% [3] - The diluted earnings per share is -0.05 yuan [3] Group 3 - The company's total asset turnover ratio is 0.17 times, and the inventory turnover ratio is 0.61 times [4] - The number of shareholders is 12,300, with the top ten shareholders holding 112 million shares, accounting for 70.03% of the total share capital [4] - The largest shareholder is Guangdong Jino Health Technology Co., Ltd., holding 45.00% of the shares [4]

Group 1 - The company did not distribute cash dividends, issue bonus shares, or increase capital from reserves during the reporting period [2] - There were no changes in the controlling shareholder or actual controller during the reporting period [3] - The company does not have any preferred shareholders or related information for the reporting period [3] Group 2 - All directors attended the board meeting that reviewed the report [1] - The company does not require retrospective adjustments or restatements of previous accounting data [2] - There are no significant matters reported during the period [3]

Core Viewpoint - The financial report of Guangdong Wannianqing for the first half of 2025 shows a slight increase in revenue but significant declines in net profit and non-recurring profit, indicating potential challenges in profitability despite stable revenue growth [1][5]. Financial Performance Summary - The company's main revenue for the first half of 2025 reached 155 million yuan, a year-on-year increase of 1.58% [1][10]. - The net profit attributable to shareholders was -7.22 million yuan, representing a year-on-year decline of 147.83% [1][10]. - The non-recurring net profit was -10.74 million yuan, down 225.53% year-on-year [1][10]. - In Q2 2025, the single-quarter main revenue was 83.97 million yuan, up 3.44% year-on-year [1][10]. - The single-quarter net profit attributable to shareholders was -3.78 million yuan, a decline of 212.4% year-on-year [1][10]. - The single-quarter non-recurring net profit was -6.09 million yuan, down 1974.12% year-on-year [1][10]. Financial Ratios - The company's debt ratio stood at 18.85% [1]. - Investment income was 2.32 million yuan, while financial expenses amounted to 634,000 yuan [1]. - The gross profit margin was reported at 63.21%, reflecting a year-on-year increase of 6.11% [1][6]. Shareholder Information - The largest shareholder is Guangdong Jino Health Technology Co., Ltd., holding 72 million shares, which accounts for 45.00% of the total [15]. - Other significant shareholders include Hehe Investment Holdings (Guangzhou) Partnership and Guangdong Qiaoyin Real Estate Development Co., Ltd., holding 16 million shares (10.00%) and 12 million shares (7.50%) respectively [15].

Group 1 - The company, Yue Wannianqing (301111), announced the appointment of Mr. Ou Zeqing as the Vice President [1]